Bioregenx (BRGX) Gains from Sales and Divestitures (2024 - 2025)
Bioregenx's quarterly Gains from Sales and Divestitures came in at $1.9 million in Q4 2025, down 68.37% year-on-year from $6.1 million in Q4 2024, and down 68.37% quarter-over-quarter from $6.1 million in Q4 2024.
Bioregenx has reported Gains from Sales and Divestitures for 2 years, with the latest figure at $1.9 million in Q4 2025.
- For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 68.37% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2025 stood at $1.9 million (down 68.37% YoY), and the FY2025 full-year result was $1.9 million, down 68.37% from the prior year.
- Gains from Sales and Divestitures for Q4 2025 stood at $1.9 million, down from $6.1 million in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $6.1 million in Q4 2024, with the low at $1.9 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Veeva Systems | 30.85 Bn | 24.28 Bn | 622.47 Mn |
| 2 | BrightSpring Health Services | 12.29 Bn | 11.41 Bn | 482.22 Mn |
| 3 | Healthequity | 7.80 Bn | 7.48 Bn | 256.31 Mn |
| 4 | Hinge Health | 4.82 Bn | 4.51 Bn | 154.23 Mn |
| 5 | Doximity | 4.21 Bn | 3.46 Bn | 125.97 Mn |
| 6 | Waystar Holding | 4.18 Bn | 4.03 Bn | 268.04 Mn |
| 7 | 10x Genomics | 3.78 Bn | 3.24 Bn | 106.18 Mn |
| 8 | Privia Health | 2.65 Bn | 2.28 Bn | 595.71 Mn |
| 9 | Omnicell | 1.95 Bn | 1.78 Bn | 140.36 Mn |
| 10 | Bioregenx | - | - | 348,288.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.94 Mn |
| Dec 31, 2025 | 1.94 Mn |
| Dec 31, 2024 | 6.12 Mn |
| Dec 31, 2024 | 6.12 Mn |
| Sep 30, 2024 | 4.04 Mn |
| Sep 30, 2024 | 4.04 Mn |
| Mar 31, 2024 | 4.04 Mn |
| Mar 31, 2024 | 4.04 Mn |